Lake Street analyst Ben Klieve lowered the firm’s price target on Bioceres (BIOX) to $5 from $8 and keeps a Buy rating on the shares. Q4 results were materially below all estimates in each segment, though the firm believes FY25 will prove to be an EBITDA trough and sees value in the next-generation products throughout Bioceres’ portfolio, the analyst tells investors in a post-earnings note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOX:
- Bioceres downgraded to Hold from Buy at Canaccord
- Bioceres Crop Solutions: Hold Rating Amid Macroeconomic Challenges and Strategic Shift
- Bioceres Crop Solutions Faces Challenging Fiscal Year
- Bioceres Crop Solutions Earnings Call Highlights Challenges and Recovery
- Bioceres Crop Solutions Faces Challenging FY25 Amid Argentine Market Pressures